Proliferation News and Research

RSS

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

Usage of rapid response teams mask systemic problems in hospitals' care for sickest patients

The growing use of rapid response teams dispatched by hospitals to evaluate patients whose conditions have suddenly deteriorated may be masking systemic problems in how hospitals care for their sickest patients, says a prominent Johns Hopkins patient safety expert.

22 Sep 2010

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Global Technology Resources, Inc., a Colorado-based I.T. integration consulting group, has announced a formal agreement with one of its strategic partners, VeriWave Inc., making GTRI one of only a handful of Gold Certified Partners in the country. By being a Gold Certified Partner, this gives GTRI the ability to advance its healthcare professional services offerings to the next level.

21 Sep 2010

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Metabolic Solutions Development Company (MSDC), will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat. The research was conducted in tissue cultures and mice.

17 Sep 2010

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Elevated levels of a growth protein in the brains of Alzheimer's disease (AD) patients is linked to impaired neurogenesis, the process by which new neurons are generated, say researchers at the University of California, San Diego in today's edition of The Journal of Neuroscience.

17 Sep 2010

Research suggests methodical approaches to control severe aggression among children with ADHD

Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine, and colleagues, found that almost half of children with attention-deficit/hyperactivity disorder whose aggressive behaviors had not been effectively controlled during routine outpatient care could achieve near absence of aggressive, explosive behavior when implementing "first-line" stimulant treatments for ADHD tailored to individual needs, along with behavioral therapy.

16 Sep 2010

Mechanism behind gene mutation leading to development of cleft palate

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.

15 Sep 2010

Long-term stenting of aortic coarctation yields 77% success rate

Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulative long-term success was 77%. Results of this study appear in the October issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

Researchers reveal new way of restraining beta-catenin to suppress tumor metastasis

Researchers reveal a new way in which cells restrain beta-catenin and potentially suppress tumor metastasis, the protein can be ejected from cells in small vesicles called exosomes. The study appears online on September 13 in the Journal of Cell Biology.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Sec. of State Clinton discusses Obama administration's foreign policy strategy

In a speech on Wednesday at the Council on Foreign Relations, Secretary of State Hillary Rodham Clinton outlined the Obama administration's approach to foreign policy and said that U.S. "global leadership is essential, even if we must often lead in new ways," the Washington Post reports.

10 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Synthetic derivative of Retinoic acid can induce cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

8 Sep 2010

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity.

8 Sep 2010

RA synthetic derivative 4-HPR's ability to induce tumour cell death

7 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences Holdings, Inc.,a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.

31 Aug 2010

Proliferation News and Research

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

Scientists develop new therapy for treatment of skin, lung cancer

Usage of rapid response teams mask systemic problems in hospitals' care for sickest patients

Recommendations for prostate cancer prevention and treatment

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Research on BMP6 protein suggests potential therapeutic target for Alzheimer's disease

Research suggests methodical approaches to control severe aggression among children with ADHD

Mechanism behind gene mutation leading to development of cleft palate

Long-term stenting of aortic coarctation yields 77% success rate

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers reveal new way of restraining beta-catenin to suppress tumor metastasis

Study finds new therapeutic target for polycystic kidney disease

Sec. of State Clinton discusses Obama administration's foreign policy strategy

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Synthetic derivative of Retinoic acid can induce cell death

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

RA synthetic derivative 4-HPR's ability to induce tumour cell death

Research on immune system can develop new therapy for inflammation, tumors

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News